Trial Profile

A Phase 1a/1b Study of ELVN-002 Combined With Trastuzumab in Advanced Stage HER2+ Solid Tumors, and ELVN-002 Combined With Trastuzumab and Chemotherapy in Advanced Stage HER2+ Colorectal Cancer and Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ELVN-002 (Primary) ; Trastuzumab (Primary) ; Capecitabine; Eribulin; Fluorouracil; Folinic acid; Oxaliplatin; Paclitaxel
Indications Advanced breast cancer; Colorectal cancer; Gastric cancer; HER2 positive breast cancer; Male breast cancer; Solid tumours
Focus Adverse reactions
Sponsors Enliven Therapeutics

18 Jul 2025 Status changed from recruiting to active, no longer recruiting.
18 Dec 2024 Planned number of patients changed from 255 to 275.
13 Aug 2024 According to an Enliven Therapeutics media release,Phase 1 monotherapy data and initial Phase 1a combination data are expected in 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com